InSilico Medicine Cayman TopCo (HKG:3696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
62.20
-3.65 (-5.54%)
At close: Apr 28, 2026
77.71%
Market Cap 37.69B
Revenue (ttm) 437.73M
Net Income (ttm) -2.74B
Shares Out 572.40M
EPS (ttm) -34.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,896,025
Average Volume 4,506,537
Open 67.00
Previous Close 65.85
Day's Range 61.05 - 67.40
52-Week Range 29.98 - 80.90
Beta n/a
RSI 49.22
Earnings Date Mar 30, 2026

About HKG:3696

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is ... [Read more]

Sector Technology
Founded 2014
Employees 317
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3696
Full Company Profile

Financial Performance

In 2025, HKG:3696's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.

Financial numbers in USD Financial Statements

News

There is no news available yet.